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2)Abstract 
Objective: Few studies have investigated the relationship between Chronic 
Obstructive Pulmonary Disease (COPD) and anxiety disorder outcomes. We 
sought to investigate the association in a large national sample. 
Methods: Cases were identified from Taiwan‟s National Health Insurance 
Research Database who were aged 15 years and above, with a new primary 
diagnosis of COPD (ICD-9:491, 492, 494 and 496) between 2000 and 2007. The 
29,951 cases identified were compared to 29,951 controls matched on sex, age, 
urban/rural residence and socioeconomic status based on insurance premium. 
Both groups were followed until the end of 2008 for instances of anxiety 
disorders. Competing risk adjusted Cox regression analyses were applied, 
adjusting for matching variables, Charlson comorbidity index, hospital admission 
days and daily dose of prednisone. 
Results: Of the 59,902 subjects, 3951 were found to have anxiety disorders 
during a mean (SD) follow-up period of 5.5 (2.5) years. COPD, female, urban 
residence, lower dose of prednisone use, depressive disorders and higher 
outpatient visits were independent predictors of incident anxiety disorder.  
Conclusions: COPD was associated with increased risk of an anxiety disorder 
diagnosis, independent of a number of potential confounding factors. 
 
Key words 
Chronic Obstructive Pulmonary Disease, Anxiety, Prednisone, Charlson 
comorbidity index, Nationwide, Cohort 
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3)Text 
Introduction 
 Chronic obstructive pulmonary disease (COPD) is an inflammatory disease 
characterized by airflow limitation with a progressive and not fully reversible 
course [1]. COPD affects 329 million people or nearly 5% of the population 
worldwide. In 2011, it ranked as the fourth leading cause of death, killing over 3 
million people[2]. COPD also impairs daily activities, social functioning, and 
quality of life, and is associated with increased healthcare costs due to its 
complex psychological comorbidities, and lengthy disease course[3, 4]. Among 
psychological comorbidities, depression and anxiety [5-7] are frequent, and more 
common in patients with COPD than the general population[8]. Although the 
relationships between COPD and anxiety have been considered, most research 
has been limited to cross-sectional studies of relatively small samples and use of 
screening questionnaires rather than physician diagnoses. A recent systematic 
review cited ten studies that had diagnosed anxiety disorders from a clinical 
interview using DSM-IV or previous versions of DSM, or ICD-10 [9]. This 
article concluded that the prevalence of clinical anxiety in patients with COPD 
ranged from 10~55% among in-patients, and 13~46% among out-patients. 
However, among these studies, only four used comparison groups, suggesting 
raised prevalence in COPD
 
[10-13]. In Asia , a recent case-control study
 
[14] 
found a 3-fold higher risk of anxiety disorder in COPD than controls (18.3% vs 
5.3%) in China, but no population-based cohort study has yet been reported in 
Asia. In addition, the association of prednisone with anxiety remains 
controversial with inconsistent results[15-18] with previous studies limited by 
cross-sectional design and small sample sizes. We describe what we believe to be 
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the first Asian population-based cohort study to investigate the role of COPD in 
the subsequent development of anxiety disorder, as well as the first 
population-based cohort study to investigate the association between prednisone 
and anxiety. 
 
Material and methods 
 
Sample 
A retrospective cohort study was assembled using data from the Taiwan 
National Health Insurance Research Database (NHIRD) provided by that 
country‟s National Health Research Institute (NHRI) which included outpatient, 
ambulatory, hospital inpatient care, as well as dental services. The National 
Health Insurance (NHI) program provides compulsory universal health insurance, 
implemented from March 1995, covering all delivery of health care in 98% of 
the national population. In cooperation with the Bureau of NHI, the NHRI 
extracted a randomly sampled representative database of 1,000,000 people from 
the year 2005 registry of all NHI enrollees using a systematic sampling method 
for research purposes, forming the Longitudinal Health Insurance Database 
(LHID). There are no statistically significant differences in age, sex, or health 
care costs between this sample and all enrollees [19].  
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COPD cases were identified based on recorded International Classification 
of Disease, Ninth revision (ICD-9) codes of 491, 492, 494 and 496. All medical 
claims made under this diagnostic code during 1997 to 2008 were collected from 
NHIRD for further analysis. The definition of COPD for this analysis required an 
inpatient diagnosis and/or at least one year‟s duration of diagnosed COPD from 
outpatient services, a definition consistent with other research using this database 
[20]. To define new cases, people who had received any COPD diagnosis in the 
medical claim data from 1997 to 1999 were excluded from the analysis. In this 
way, 29,951 new COPD cases aged more than 15 years were identified. For 
assessing the association between COPD and anxiety disorder risk, one control 
per case was randomly sampled from the remaining sample, matching for sex, 
age within 1 year, urban/rural residence and insurance premium (a marker of 
socioeconomic status; see below). Both cases and controls were followed for 
diagnosed anxiety disorder as an outcome. Anxiety disorders were defined in this 
study on the basis of ICD-9 codes 300.0, 300.01, 300.02, 300.2, 300.21, 300.23 
and 300.3. All study patients without anxiety disorder diagnosis before the index 
date. The index date was the first COPD diagnosis date, and this was also 
assigned to the respective matched controls, who were NHI enrollees without an 
anxiety disorder diagnosis before the index date. 
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Covariates considered in this analysis included age, sex, area of residence 
(urban/rural), insurance premium, prednisone use, Charlson comorbidity index 
and hospital admission days. The insurance premium served as an indicator of 
economic status and was classified into one of three categories: fixed premium 
and dependent, monthly income less than 20,000 New Taiwan Dollars (NTD), 
and NTD 20,000 or more (1US $ = 32.1 NTD in 2008). The fixed premium 
group comprised those requiring social welfare support, which included 
low-income citizens and veterans. The „dependent‟ insurance group referred to 
family members who did not have a fixed salary income. Only prednisone use 
for at least one year was classified as use. The annual average cumulative 
defined daily dose (DDD) of prednisone was calculated and divided into 3 
groups (0, 1-29, 30+). The defined daily dose recommended by the WHO is a 
unit for assessing the standard dose of drug. Cumulative DDD, which indicates 
the exposed duration of drug use for a period, was estimated as the sum of 
dispensed DDDs of a drug within a time period. The annual average cumulative 
DDD was used to assess the dose usage of prednisone in the follow-up time 
period. General physical health was quantified using the Charlson comorbidity 
index which comprises a summation of diseases weighted on the basis of their 
association with mortality [21] as of the index date.“Hospital admission days” 
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for any disorder during any period was also included as an indicator of general 
health. The Charlson comorbidity index and hospital admission days were 
measured prior to the outcome since 1997. 
 
Statistical analysis 
Death prior to anxiety disorder was considered as a competing risk event. 
The death date was retrieved from the national mortality database. The 
death-adjusted cumulative incidences of anxiety disorder were calculated using 
the Fine and Gray method [22]. Each person‟s first presentation within the study 
period was used in the calculation of outcome risk over given time intervals. The 
risk of anxiety disorder during the follow-up period was calculated using 
survival analysis, with the time function represented by the number of years from 
the index date of COPD diagnosis to December 31, 2008 (end of follow-up) or 
until the date of death or migration if earlier. Competing risk adjusted Cox 
regression models [22] were fitted to estimate associations between COPD and 
anxiety disorder, adjusting for covariates. All data management was performed 
using SAS 9.3 software (SAS Institute Inc., Cary, NC, USA). Calculations of 
cumulative incidences and Cox models in the competing risk analysis were 
carried out using the R package “cmprsk” [23]. 
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Time-dependent Cox regression model was used for multivariate assessment of 
prednisone use on anxiety disorder by controlling the potential confounding 
covariates. Instead of modeling prednisone as a cumulative effect by calculating the 
cumulative annual average DDD during the follow-up period, time-dependent model 
can take dynamic changing of prednisone use into account by assessing the yearly 
DDD of prednisone use effect during the following period in this study. Hazard ratios 
(HRs) and 95% confidence interval (CI) for bipolar were reported and comparing to 
the main analysis. 
We classified anxiety diagnosis as two categories: (1) 300.0 (anxiety state) (2) 
„specified anxiety‟, including 300.01(panic disorder), 300.02(generalized anxiety 
disorder), 300.2(phobic disorders), 300.21(agorophobia), 300.23(social anxiety 
disorder) and 300.3(obsessive-compulsive disorder). Besides, we also classified 
anxiety diagnosis as „diagnosed by psychiatrist‟ and „diagnosed by other physician‟. 
The frequency of these two kinds of classification was reported. In order to reveal 
these diagnosis effects on our results, we performed sensitivity analysis which only 
focused on „specified anxiety‟ and „diagnosed by psychiatrist‟, respectively. The 
anxiety state and „diagnosed by other physician‟ type of anxiety were considered as 
competing event and adjusted by competing Cox regression model. 
 
Results 
  The two cohorts consisted of 29,951 people with newly-diagnosis COPD 
and 29,951 matched controls ascertained from the database covering 2000-2007. 
Cohort characteristics are described and compared in Table 1. Of the COPD 
cases, 60% were male and highest numbers were in the 65+ year range. More 
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than 70% were urban residents and one-third were receiving social welfare 
support or were dependent on their family. The COPD cohort used steroid 
during follow-up more frequently than the control cohort. The mean Charlson 
comorbidity index, hospital admission days and outpatient visits were higher in 
the COPD cohort than in the control cohort (T-test p<0.001). 
 
Insert Table 1 here 
 
   Of the total 59,902 subjects, 3951 received a diagnosis of an anxiety disorder 
during the surveillance period: 2735 (9.13%) in the COPD cohort and 1216 
(4.06%) in the control cohort. The mean (SD) follow-up interval for all subjects 
was 5.5 (2.5) years (Table 1). The anxiety disorder incidence for the COPD 
cohort was 1674.3 per 10
5
 person-years (95% CI: 1612.1-1738.3) and that for the 
control cohort was 744.4 per 10
5
 person-years (95% CI: 703.2-787.5). 
Kaplan-Meier analysis of cumulative incidence showed that patients with COPD 
had a significantly higher rate of incident anxiety disorders than the non-COPD 
group (p < 0.001; modified log-rank test) (Figure 1).  
   Insert Figure 1 here 
 
Analyses of associations of interest are summarized in Table 2. In the fully 
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adjusted Cox regression model from the competing risk analysis, COPD was 
positively associated with anxiety disorder (HR 2.50, 95% CI 2.33-2.69, 
p<0.001). Additional factors associated with anxiety disorder incidence were 
female, urban residence, lower dose of prednisone use, depressive disorders and 
higher outpatient visits. 
Insert Table 2 here 
 
Factors associated with anxiety disorder incidence among the COPD cohort 
were similar with the main finding of all study patients‟ analysis (Table 3). In the 
stratified analyses, associations of interest were significant on the basis of sex 
and age in the fully adjusted Cox regression models (Table 4). The interaction 
were significant of COPD by gender and COPD by age group (both 
P<0.001).The negative association results between prednisone use and anxiety 
disorder were similar both in cumulative effect analysis (Table 3) and yearly 
dynamic effect time-dependent analysis (Table 5).  
Of 3951 anxiety events in our main analysis, 3527 (89.27%) for anxiety 
state diagnosis and 424 (10.73%) for specified anxiety; 3360 (85.04) diagnosed 
by other physician and 591 (14.96%) diagnosed by psychiatrist. When we 
focused on specified anxiety diagnosis as interest event and considered anxiety 
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state as competing event to perform competing Cox regression analysis, the 
COPD was also positive associated with anxiety, adjusted hazard ratio=2.51, 
95% CI:2.01-3.14.  Besides, the sensitivity analysis which focused on anxiety 
diagnosed by psychiatrist was also similar to the main analysis, adjusted hazard 
ratio=2.32, 95% CI:1.92-2.80. 
 
Insert Table 3 here 
Insert Table 4 here 
Insert Table 5 here 
 
Discussion  
To our knowledge, our study is the first nationwide population-based cohort 
study to investigate specifically the association between COPD and the risk of 
subsequent anxiety disorders in an Asian population. The cumulative incidence 
of anxiety disorder in a cohort of newly diagnosed COPD remained higher than 
in a non-COPD matched comparison group over a mean follow-up period of 5.5 
years (Table 1) with an unadjusted hazard ratio of 2.21. After further adjusting 
for a number of potential confounding factors, the hazard ratio remained little 
changed at 2.22 (HR 2.22; 95% CI 2.07 to 2.38). The finding is similar to that of 
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cross-sectional studies, showing that anxiety disorders are highly prevalent 
among COPD-participants with a prevalence two to three times higher than 
among non-COPD participants [10, 13, 14, 24, 25]. Compared to the finding of 
Wagena‟s Maastricht Study [26], a prospective population-based cohort study set 
up among Dutch employees to investigate the association of COPD and 
subsequent anxiety, our association was not as strong as their odds ratio of 5.09 
(95% CI 2.91 to 8.89) for COPD and risk of anxiety (after controlling for sex, 
age, educational level and smoking status). Asian patients have been found to be 
more unwilling than Western patients to reveal or admit feelings of anxiety due 
to perceived stigma of mental illness, which may have given rise to a relative 
lower risk [27].  
 We also found that that female COPD patients are more likely than men to 
have anxiety, which is consistent with reports from previous studies [14, 28, 29]. 
In addition, an overlap between anxiety and depressive symptoms in patients 
with COPD is common and may increase the prevalence of patients with anxiety 
disorder [30, 31], although in our study COPD remained associated with an 
increased risk of anxiety disorder even after adjusting for depression.  
 Our study is also the first study to evaluate the association between prednisone 
use and anxiety in a national sample, finding negative association between the 
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dose of prednisone and the development of anxiety disorders in COPD. Previous 
study showed COPD patients receiving prednisone treatment had significant 
improvements in dyspnea [32] and this might be linked to lower anxiety. 
Although an animal study reported that prednisone causes anxiety-like behaviors, 
suggesting that altered gene expressions related to hippocampal remodeling or 
damage are involved in such behavioral changes [33], previous human studies 
have given rise to inconsistent results over the relationship of prednisone use and 
anxiety in asthma. Three studies have reported that anxiety was associated with 
increased use of prednisone[15-17] while other two studies found no significant 
relationship[18, 34]. However, most were limited by cross-sectional designs 
and/or small sample sizes.  
It remains unclear why there is a high prevalence of anxiety in patients with 
COPD. The causal pathway between COPD and anxiety is complex, overlapping 
and maybe bidirectional[35] . Several theories have been proposed to explain the 
association. In Pumar‟s review article, shortness of breath (hyperventilation), the 
main symptom of COPD, can lower pCO2 and cause respiratory alkalosis. This 
pattern of breathing (dyspnea) is usually a source of anxiety and consequently 
evokes panic attacks. In turn, it is possible to evoke symptoms of dyspnea in 
panic disorder patients when infusing lactate or inhaling excessive CO2 [36]. In 
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addition, cerebral hypoxia is probably involved in the causation of symptoms of 
anxiety in sufferers of COPD[37]. Brain image studies also suggest a shared 
etiology between anxiety and dyspnea, and dyspnea is processed in the same 
brain areas (amygdala and wider limbic system) that process fear and anxiety [38, 
39]. Cognitive behavior models offer another important theory. Clark‟s model 
proposes that normal bodily sensations are catastrophically misinterpreted as 
dyspnea by patients with panic disorder, causing a consequent panic attack [40]. 
Furthermore, patients with COPD often have comorbid depression and an 
overlap between depressive and anxiety symptoms is common. Thus, depression 
itself may play a significant role to increase the prevalence of anxiety disorder in 
patients with COPD. 
This study had several strengths. Most previous studies addressing 
comorbid anxiety in patients with COPD have been cross-sectional which does 
not allow conclusions to be drawn about the temporal relationship between 
COPD and anxiety disorders. In addition, research to date has been 
predominantly confined to Western populations, as well as having small sample 
sizes and lacking control groups, thus limiting wider generalizability. Our study 
addressed these limitations. Nonetheless, there are also important limitations, 
particularly arising from the use of routine data, such as lack of information on 
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other important potential confounders, including stressful life events, family 
history, and especially smoking history. The diagnosis for COPD and anxiety 
disorders was based on the physicians‟ diagnosis and measurement bias cannot 
be excluded. In addition, we were not able to assess the relationships between the 
severity of COPD and the level of anxiety disorder, due to lack of data. In regard 
to the association of prednisone and anxiety disorders, the level of prednisone 
use were defined by Defined Daily Dose which does not allow medication 
patterns to be examined such as whether prednisone was received long-term or 
short-term, on a daily basis or in intermittent. In addition, more than 90% of the 
sample falls into the lowest prednisone dose category. This leaves considerable 
potential for residual confounding when used as a covariate. 
 
Conclusion 
Our findings from a national health insurance dataset found a link between 
COPD and anxiety disorders. Given the high and rising prevalence of COPD, 
clinicians need to be particularly aware of the occurrence of anxiety disorder and 
psychological or pharmacological interventions should be initiated. Further 
research is needed to explore underlying mechanisms linking these two adverse 
health outcomes.  
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Table 1 Characteristics of COPD cases and their matched 
a
 controls in Taiwan, 
2000-2007. 
Characteristic 
COPD  Non-COPD
a
 Chi-square 
 test p value N %  N % 
Sex       
Female  11945 39.88  11945 39.88 >0.99 
Male 18006 60.12  18006 60.12  
Age group , year       
15-24 1022 3.41  1022 3.41 >0.99 
25-44 5371 17.93  5371 17.93  
45-64 10873 36.3  10873 36.3  
65+ 12685 42.35  12685 42.35  
Age, year (mean±SD) 59.05±16.69  59.02±16.65 0.789 
Residence       
Rural  8845 29.53  8845 29.53 >0.99 
Urban 21106 70.47  21106 70.47  
Insurance premium       
Fixed premium and dependent 9364 31.26  9364 31.26 >0.99 
Less than NTD
 b
 20,000 7782 25.98  7782 25.98  
NTD 20,000 or more 12805 42.75  12805 42.75  
Prednisone, Define Daily Dose (DDD)     
0  9963 33.26  17493 58.41 <0.001 
1-29 11171 37.30  9598 32.05  
30+ 8817 29.44  2860 9.55  
Anxiety disorder
 c
       
No  27216 90.87  28735 95.94 <0.001 
Yes 2735 9.13  1216 4.06  
Depression disorder
 d
       
No  28903 96.5  29411 98.2 <0.001 
Yes 1048 3.5  540 1.8  
Charlson index (mean±SD) 1.98±2.13  1.17±1.81 <0.001 
Hospital admission days (days, 
mean±SD) 
14.61±90.55  6.66±56.79 <0.001 
Outpatient (visits, mean±SD) 26.01±20.49  15.64±16.05 <0.001 
a
Matched by sex and age (±1 years old). 
b
 1 USD = 32.1 NTD in 2008 
c
ICD-9:300.0,300.01,300.02,300.2,300.21,300.23,300.3. 
d
ICD-9: 296.20~296.36, 296.82, 300.4, 311 
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Table 2 Competing risk adjusted Cox regression analysis on anxiety disorder in Taiwan, 
2000-2007 
Variable 
Unadjusted hazard ratio  Adjusted hazard ratio 
Estimate (95% CI
 a
)  P value  Estimate (95% CI 
a
) P value 
COPD      
No 1.00   1.00  
Yes 2.21 (2.06-2.36) <0.001  2.50 (2.33-2.69) <0.001 
Sex       
Female  1.00   1.00  
Male 0.59 (0.55-0.62) <0.001  0.65 (0.61-0.69) <0.001 
Age (10 years)      
 1.03 (1.01-1.04) 0.002  1.02 (1.00-1.03) 0.129 
Residence      
Rural 1.00   1.00  
Urban  1.08 (1.01-1.15) 0.031  1.15 (1.07-1.24) <0.001 
Insurance premium      
Fixed premium and 
dependent 
1.00   1.00  
Less than NTD
 b
 20,000 0.93 (0.87-1.00) 0.057  0.93 (0.86-1.02) 0.113 
NTD 20,000 or more 0.97 (0.91-1.03) 0.347  0.99 (0.91-1.07) 0.749 
Prednisone, DDD
 c
      
0  1.00   1.00  
1-29 0.58 (0.54-0.62) <0.001  0.43 (0.40-0.47) <0.001 
30+ 0.38 (0.34-0.42) <0.001  0.21 (0.19-0.23) <0.001 
Depression disorder
 d
, yes 2.70 (2.37-3.08) <0.001  2.43 (2.18-2.72) <0.001 
Charlson comorbidity 
index 
1.04 (1.03-1.05) <0.001  0.93 (0.80-1.08) 0.179 
Hospital admission days 
(100 days) 
0.94 (0.83-1.06) 0.291  0.94 (0.79-1.10) 0.191 
Outpatient (10 visits) 1.19 (1.17-1.20) <0.001  1.21 (1.19-1.23) <0.001 
a
CI: Confidence interval. 
b
 1USD = 32.1 NTD in 2008 
c
 DDD: Define daily dose 
d
ICD-9: 296.20~296.36, 296.82, 300.4, 311 
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Table 3 Competing risk adjusted Cox regression analysis on anxiety disorder among COPD 
patients in Taiwan, 2000-2007 
Variable 
Unadjusted hazard ratio  Adjusted hazard ratio 
Estimate (95% CI
 a
)  
P 
value 
 Estimate (95% CI 
a
) P value 
Sex       
Female  1.00   1.00  
Male 0.61 (0.57-0.66) <0.001  0.69 (0.64-0.75) <0.001 
Age (10 years)      
 1.00 (0.98-1.02) 0.967  1.01 (0.98-1.03) 0.669 
Residence      
Rural 1.00   1.00  
Urban  1.08 (0.99-1.17) 0.074  1.18 (1.08-1.29) <0.001 
Insurance premium      
Fixed premium and dependent 1.00   1.00  
Less than NTD
 b
 20,000 0.93 (0.85-1.01) 0.101  0.92 (0.83-1.02) 0.130 
NTD 20,000 or more 1.02 (0.94-1.10) 0.675  0.99 (0.90-1.09) 0.807 
Prednisone, DDD 
c
      
0  1.00   1.00  
1-29 0.43 (0.39-0.46) <0.001  0.39 (0.36-0.43) <0.001 
30 + 0.24 (0.21-0.26) <0.001  0.20 (0.17-0.22) <0.001 
Depression disorder
 d
 2.23 (1.92-2.59) <0.001  2.31 (2.04-2.61) <0.001 
Charlson comorbidity index 0.99 (0.97-1.00) 0.142  0.93 (0.78-1.09) 0.251 
Hospital admission days (100 
days) 
0.80 (0.61-1.04) 0.092  0.98 (0.83-1.14) 0.212 
Outpatient (10 visits) 1.14 (1.12-1.15) <0.001  1.19 (1.17-1.21) <0.001 
a
CI: Confidence interval. 
b
 1USD = 32.1 NTD in 2008 
c
 DDD: Define daily dose 
d
ICD-9: 296.20~296.36, 296.82, 300.4, 311 
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Table 4 Association between COPD and anxiety disorder by gender and age group, 
2000-2007 
Subgroup 
Adjusted hazard ratio on anxiety disorder 
Estimate (95% CI
b
) P value 
Total 2.50 (2.33-2.69) <0.001 
Sex   
Male 2.81 (2.52-3.13) <0.001 
Female 2.25 (2.04-2.49) <0.001 
Age group   
 15-24 3.68 (1.88-7.24) <0.001 
 25-44 2.81 (2.30-3.44) <0.001 
 45-64 2.33 (2.09-2.61) <0.001 
 65+ 2.51 (2.24-2.81) <0.001 
a
Competing risk adjusted Cox regression analysis controlling by gender, age, residence, 
insurance premium, prednisone, depression disorder (ICD-9: 296.20~296.36, 296.82, 
300.4, 311), Charlson comorbidity index, hospital admission days, outpatient visits 
and mortality.
 
b
CI: Confidence interval. 
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Table 5 Time dependent Cox regression analysis on anxiety disorder in Taiwan, 2000-2007 
Variable  
Adjusted Hazard ratio 
(95% CI 
a
) 
P value 
COPD    
No  1.00  
Yes  1.50 (1.43-1.57) <0.001 
Sex     
Female   1.00  
Male  0.62 (0.59-0.65) <0.001 
Age (10 years)    
  1.08 (1.07-1.09) <0.001 
Residence    
Rural  1.00  
Urban   0.94 (0.90-0.99) 0.013 
Insurance premium    
Fixed premium and 
dependent 
 1.00  
Less than NTD
 b
 
20,000 
 1.04 (0.98-1.10) 0.170 
NTD 20,000 or more  1.05 (1.00-1.11) 0.055 
Prednisone, DDD
 c
    
0   1.00  
1-29  0.69 (0.65-0.73) <0.001 
30 +  0.51 (0.45-0.58) <0.001 
Depression disorder 
d
  2.63 (2.38-2.91) <0.001 
Charlson comorbidity 
index 
 0.95 (0.80-1.11) 0.324 
Hospital admission 
days (100 days) 
 0.92 (0.77-1.08) 0.411 
Outpatient (10 visits)  1.18 (1.17-1.19) <0.001 
a
CI: Confidence interval. 
b
 1USD = 32.1 NTD in 2008 
c
 DDD: Define daily dose 
d
ICD-9: 296.20~296.36, 296.82, 300.4, 311 
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Figure 1 Cumulative incidence of anxiety disorder by study groups (COPD VS 
Non-COPD). Modified log-rank test p value<0.001.
 
